RIVANNA, a medical device manufacturer, announces the results of a report on anesthesiology employment across the United States, finding significant variability across states. Brandon Togioka, M.D., says, "These data provide important insights into the evolving distribution of anesthesiology professionals, which is vital for addressing care gaps."

SpliceBio, a biotech company, announces that the FDA cleared its investigational new drug application for SB-007, the only clinical-stage therapeutic addressing the root genetic cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations. Paul Yang, M.D., Ph.D., says, "This new therapy utilizes a unique approach to replace the full-size, normal ABCA4 protein at high efficiency, which addresses the root cause of Stargardt disease across any pathogenic variant in the ABCA4 gene. This IND clearance represents a major milestone in the field, and I am thrilled to be part of the clinical studies exploring this promising approach that could transform the lives of Stargardt disease patients."

In a Public News Service story about Kentucky residents being notified that their lead water pipes could be posing a health danger, Leah Werner, M.D., notes that residents can test their own water: "Really the best way to do that is to look at your either your city government website. Beyond that, the government is mandated to help you with testing kits, but Home Depot and places like that also sell lead testing kits."

Gopal Allada, M.D., comments on a new study that concludes long-term exposure to air pollution poses an increased risk of blood clots in deep veins, which can result in serious complications, including death. He notes that the study doesn't prove a causal link: "There may be something else that is causing increased cases of VTE more commonly in areas with greater air pollution."

Gopal Allada, M.D., comments on a new study that concludes long-term exposure to air pollution poses an increased risk of blood clots in deep veins, which can result in serious complications, including death. He notes that the study doesn't prove a causal link: "There may be something else that is causing increased cases of VTE more commonly in areas with greater air pollution."

ADDitude Magazine covers a new study that finds exposure to leaded gasoline from car exhaust was tied to population-wide cases of mental health disorders, estimating that more than half of the current U.S. population was exposed to harmful levels of lead in childhood. Joel Nigg, Ph.D., says, “Research on lead as a developmental neurotoxicant is robust. Its correlation with ADHD is also well established. Even low levels of exposure have an effect on ADHD.”

Megan Burger, Ph.D., receives a research grant from the Lung Cancer Research Foundation focused on optimizing immunotherapy sequencing to overcome resistance: PR Newswire release picked up by outlets across the country.

Roseburg philanthropists Cheryl and Allyn Ford donate $16 million to establish a comprehensive clinic for children with pediatric neuromuscular disorders. Erika Finanger, M.D., says, “For years I have dreamed of a one-stop clinic where kids and their families can access all the right people and services in one place and in one day. Thanks to this incredibly generous gift, that dream will soon come true.”

Peptomyc announces the approval of a Research Investigational New Drug (IND) application for a new clinical trial in collaboration with the OHSU Knight Cancer Institute and the OHSU Brenden-Colson Center for Pancreatic Care to evaluate OMO-103 in patients with a form of pancreatic cancer. Charlie Lopez, M.D., Ph.D., says, “We are excited to collaborate with Peptomyc on this important trial. By conducting this study, we hope to gain valuable insights that will ultimately lead to improved outcomes for cancer patients.”

Immunovia announces the completion of a promising study to detect early-stage pancreatic ductal adenocarcinoma. Rosalie Sears, M.D., says, “This study validates the high accuracy of the Immunovia test in detecting stage 1 and 2 pancreatic cancer in a challenging high-risk population.”